Abstract 5887
Background
Tumour tissue from individual patients with colorectal cancer may be cultured in vitro as three-dimensional tumoroids that resembles the biological features in vivo including chemotherapy sensitivity and resistance. Tumoroid formation is well-established for resected tumour tissue, but there is a lack of detailed descriptions of cultivating tumoroids from liver biopsies. The purpose of this study was to compare metastasis, imaging, biopsy histology and tumoroid yield.
Methods
Patients exposed to all standard medical treatment for metastatic colorectal cancer were included within an ongoing phase II clinical trial (NCT03251612). Biopsies from liver were obtained with 16G needles and other localizations 18G. Microscopy was used to evaluate necrosis (present or not) and to quantify the fraction of vital carcinoma cells: 0 (0%), 1 (0-10%), 2 (10-50%) or 3 (50-100%). Tumoroid formation was quantified as 0 (0 tumoroids), 1 (1-10), 2 (10-100), 3 (100-1000) or 4 (>1000). Biopsies of low quality were pooled up to three together for tumoroid formation. Elastography during ultrasound were used to measure the tissue stiffness of a subset of liver metastases and was together with metastasis size other explorative variables.
Results
A total of 78 biopsies from 27 biopsy sessions were included from liver (22), lung (2), carcinomatosis (1), muscle (1) or kidney (1). No serious adverse events related to biopsy procedures were observed. 37 (49%) of 76 biopsies for histology contained vital carcinoma cells and necrosis was present in 43 (57%). The number of tumoroids after cultivation correlated with the level of vital carcinoma cells in biopsies (p = 0.008) and trend-wise inversely with the stiffness of the tumour (p = 0.05) but not the size of metastasis (p = 0.97) nor presence of necrosis (0.98).
Conclusions
The tumoroid yield after cultivation of biopsies from chemo-refractory colorectal cancer patients correlates with the level of carcinoma cells determined by microscopy and probably with the stiffness of the metastasis. Necrosis and size of metastasis were not related. These findings may have great implications for selecting and evaluating biopsies for tumoroid formation in precision medicine to colorectal cancer patients.
Clinical trial identification
NCT03251612.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
2cureX.
Disclosure
L.H. Jensen: Research grant / Funding (institution): MSD; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): 2cureX. G. Hagel: Shareholder / Stockholder / Stock options, Full / Part-time employment: 2cureX. H. Harling: Advisory / Consultancy: 2cureX. O. Thastrup: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: 2cureX. All other authors have declared no conflicts of interest.
Resources from the same session
3191 - The efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the phase 3 trial (REFLECT trial) and those with BCLC Stage B hepatocellular carcinoma - A nationwide multicenter study in Japan-
Presenter: Azusa Sakamoto
Session: Poster Display session 2
Resources:
Abstract
1529 - Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase 3 studies (REACH, REACH-2)
Presenter: Andrew Zhu
Session: Poster Display session 2
Resources:
Abstract
2767 - Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the CELESTIAL study
Presenter: Nicholas Freemantle
Session: Poster Display session 2
Resources:
Abstract
2150 - Alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase 3 RESORCE trial
Presenter: Jordi Bruix
Session: Poster Display session 2
Resources:
Abstract
3437 - Phase I/II trial of NBTXR3 activated by SBRT in patients with hepatocellular carcinoma or liver metastasis
Presenter: Marc Pracht
Session: Poster Display session 2
Resources:
Abstract
1758 - Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase 3 trials (REACH and REACH-2)
Presenter: Masatoshi Kudo
Session: Poster Display session 2
Resources:
Abstract
1192 - Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure–response analysis
Presenter: Josep Llovet
Session: Poster Display session 2
Resources:
Abstract
1600 - Outcomes of Hepatocellular Carcinoma (HCC) Patients Treated with Nivolumab: The Mount Sinai Hospital Experience.
Presenter: Sirish Dharmapuri
Session: Poster Display session 2
Resources:
Abstract
2364 - Pembrolizumab vs Chemotherapy in Patients With Advanced/Metastatic Adenocarcinoma (AC) or Squamous Cell Carcinoma (SCC) of the Esophagus as Second-Line Therapy: Analysis of the Chinese Subgroup in KEYNOTE-181
Presenter: Jia Chen
Session: Poster Display session 2
Resources:
Abstract
1933 - A national comparative effectiveness study to assess definitive chemoradiation regimens in proximal oesophageal squamous cell cancer
Presenter: Judith de Vos-Geelen
Session: Poster Display session 2
Resources:
Abstract